VX-548 for Acute Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing VX-548, a new drug aimed at reducing sudden, severe pain. It focuses on patients who need quick pain relief. VX-548 works by blocking pain signals from reaching the brain.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data exists for VX-548 in humans?
How does the drug VX-548 for acute pain differ from other treatments?
VX-548 is unique because it is a novel treatment option for acute pain, potentially involving a mechanism similar to N-type calcium channel blockers like ω-conotoxin MVIIA, which are known for their potent analgesic effects by inhibiting pain-related neurotransmitter release in the nervous system.678910
Are You a Good Fit for This Trial?
This trial is for adults with a BMI between 18.0 and 40.0 who are experiencing new, moderate to severe acute pain, rated ≥4 on the numeric scale. It includes both surgical patients with postoperative pain and non-surgical individuals with new pain not related to any known condition.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VX-548 every 12 hours for up to 14 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VX-548
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vertex Pharmaceuticals Incorporated
Lead Sponsor
Dr. David Altshuler
Vertex Pharmaceuticals Incorporated
Chief Medical Officer since 2020
MD, PhD
Dr. Reshma Kewalramani
Vertex Pharmaceuticals Incorporated
Chief Executive Officer since 2020
MD, trained in internal medicine and nephrology